Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Disulfiram Toxicity

  • Author: Samara Soghoian, MD, MA; Chief Editor: Asim Tarabar, MD  more...
 
Updated: Jan 06, 2016
 

Background

Disulfiram (tetraethylthiuram disulfide [TETD]) has been used for more than 50 years as a deterrent to ethanol abuse in the management of alcoholism. Approximately 200,000 alcoholics take disulfiram, or Antabuse, regularly in the United States.[1]

The first suggestion that disulfiram might be used in the treatment of alcoholism came in 1937 when an American physician noted that workers in the rubber industry who were exposed to TETD developed a reaction after drinking ethanol. A decade later, two Danish researchers at the Royal Danish School of Pharmacy in Copenhagen made the same discovery. Jens Hald and Eric Jacobsen were experimenting with disulfiram as a potential antihelminthic, and each took small doses to determine potential side effects in humans. Several days later, they attended a cocktail party and both became ill. They concluded that the facial flushing and tachycardia they experienced must be due to the disulfiram.

Soon thereafter, physicians began prescribing disulfiram as a deterrent to ethanol abuse. It has also been proposed as a deterrent to cocaine abuse, and several studies have suggested improved retention rates in treatment programs for cocaine-dependent individuals treated with disulfiram. A study found diminished "high" or "rush" after intravenous cocaine administration to healthy volunteers pretreated with disulfiram, with no change in cardiovascular parameters.[2]

The disulfiram-ethanol reaction (DER) is due to increased serum acetaldehyde concentrations generated by the metabolism of ethanol by alcohol dehydrogenase in the liver. Normally, this acetaldehyde is cleared rapidly by its metabolism to acetate via aldehyde dehydrogenase.[3] Disulfiram blocks this enzyme, irreversibly inhibiting the oxidation of acetaldehyde and causing a marked increase in acetaldehyde concentrations after ethanol consumption. The discomfort associated with this syndrome is intended to serve as a negative stimulus, but the reaction may be severe enough to cause hypotension and death.

In considering disulfiram toxicity, a distinction must be made between the clinical manifestations of a disulfiram-ethanol reaction (DER) and the toxic effects of disulfiram itself. Direct disulfiram toxicity may be further divided into acute poisoning versus chronic poisoning. The directly toxic effects of disulfiram include neurologic, cutaneous, and hepatotoxic sequelae in addition to the disulfiram-ethanol reaction.

Disulfiram received US Food and Drug Administration (FDA) approval for use in the treatment of alcoholism in 1951. At that time, it was commonly prescribed in very high doses, up to 3,000 mg a day in some cases. This resulted in a relatively high rate of extremely severe or fatal reactions. Today, much lower doses are used, and the incidence of disulfiram toxicity has waned. In 2014, the American Association of Poison Control Centers reported 61 single exposure cases, with no deaths.[4]

Next

Pathophysiology

Ethanol is mainly metabolized in the liver to acetaldehyde by alcohol dehydrogenase (ADH). Acetaldehyde is then oxidized to acetate by aldehyde dehydrogenase (ALDH). Disulfiram irreversibly inhibits the oxidation of acetaldehyde by competing with the cofactor nicotinamide adenine dinucleotide (NAD) for binding sites on ALDH (see the image below).

The pathway of ethanol metabolism. Disulfiram redu The pathway of ethanol metabolism. Disulfiram reduces the rate of oxidation of acetaldehyde by competing with the cofactor nicotinamide adenine dinucleotide (NAD) for binding sites on aldehyde dehydrogenase (ALDH).

Ultimately, disulfiram reduces the rate of oxidation of acetaldehyde, causing a 5- to 10-fold increase in the concentration of acetaldehyde. An increased serum acetaldehyde concentration is thought to be responsible for the unpleasant side effects associated with the disulfiram-ethanol reaction.

Disulfiram also directly inhibits hepatic microsomal enzymes (cytochrome P450), in particular CYP2E1. This interferes with the metabolism of certain drugs, most notably that of warfarin, phenytoin, and theophylline. Disulfiram may also decrease the clearance of some benzodiazepines (diazepam, oxazepam, and chlordiazepoxide), caffeine, and some tricyclic antidepressants (desipramine and imipramine). The resulting possible elevation of serum concentrations of these medications has the potential to cause a corresponding toxicity.

Disulfiram is highly lipid soluble (accumulates in adipose tissue, crosses blood-brain barrier), highly protein-bound, and has 80% bioavailability after an oral dose of 350 mg. Approximately 5-20% is not metabolized and is excreted unchanged in the feces; the remainder is metabolized to both toxic and nontoxic metabolites. The elimination of disulfiram and its numerous metabolites is a very slow process. Approximately 20% of the drug remains in the body for 1-2 weeks postingestion. Most of these metabolites are then eliminated through the gastrointestinal (GI), renal, and respiratory routes. The prolonged effects of disulfiram occur not only because the drug is slowly eliminated from the body but also because it irreversibly inhibits aldehyde dehydrogenase. In order to regain the ability to metabolize acetaldehyde, the individual must therefore synthesize new stores of the enzyme.

Disulfiram metabolites cause clinically important effects in the body (see the image below).

Disulfiram, prodrug for active metabolites. Disulfiram, prodrug for active metabolites.

The most important toxic metabolites are diethyldithiocarbamate (DDC) and its metabolite carbon disulfide (CS2). DDC chelates copper, thus impairing the activity of dopamine beta-hydroxylase, an enzyme that catalyzes the metabolism of dopamine to norepinephrine. In this way, DDC causes depletion of presynaptic norepinephrine and accumulation of dopamine. Although hypotension from the disulfiram-ethanol reaction is mainly attributable to the effects of acetaldehyde, depletion of the potent vasoconstrictor norepinephrine may also be a contributing factor.

Dopamine agonism may be implicated in some of the altered behavior associated with disulfiram toxicity. Although no studies have directly examined the effects of low doses of disulfiram on psychotic symptoms, hypomania and psychosis have been documented in many reports among alcoholics taking high-dose disulfiram (up to 2,000 mg/d). It is possible that disulfiram, like L-dopa and amphetamine, unmasks or exacerbates preexisting psychotic symptoms in susceptible individuals by increasing central dopamine levels.

Neurotoxic effects associated with disulfiram include extrapyramidal symptoms, and lesions of the basal ganglia have been described in patients after therapy with disulfiram. Potential mechanisms for disulfiram-associated neurotoxicity include abnormal CNS metal accumulation from the chelation of copper by DDC, leading to free radical formation and neuronal oxidative stress. In addition, one study found that disulfiram and DDC increase the release of glutamate from striato-cortical synaptic vesicles, both in vitro and in rats, suggesting yet another possible mechanism for DDC-mediated neuronal damage.[5]

Other mechanisms implicated in DDC’s cytotoxic effects include its ability to chelate nickel, to interfere with sulfhydryl groups in cytochrome P-450 enzymes, and to inhibit ADH and ALDH enzymes. Furthermore, DDC inhibits superoxide dismutase, thereby impairing the ability to eliminate free radicals. DDC-induced methemoglobinemia can also occur secondary to impairment (consumption) of glutathione-dependent methemoglobin reduction.

Carbon disulfide (CS2), another disulfiram metabolite from DDC metabolism, has neurotoxic effects when administered directly. Acute exposure to CS2 causes rapid onset of headache, confusion, nausea, hallucinations, delirium, seizures, coma, and potentially death. CS2 may cause seizures by interacting with pyridoxal-5-phosphate, a cofactor in the production of GABA from glutamate, thereby depleting GABA levels in the brain and leading to benzodiazepine-resistant seizures; this forms the basis for an important experimental rat model of status epilepticus. In addition to its neurotoxic effects (neurobehavioral toxin), CS2 is hepatotoxic, inhibits cytochrome P-450, and is cardiotoxic.

The mechanism by which chronic disulfiram therapy produces hepatotoxicity is not well understood and may involve hypersensitivity or immunologic reactions in addition to the direct cytotoxic effects of its metabolites.

Previous
Next

Epidemiology

Mortality/Morbidity

Disulfiram toxicity has a particular classification with significant overlap. The first type of toxicity is the classic disulfiram-ethanol reaction, known as the acetaldehyde syndrome. Secondly, disulfiram has its own associated acute and chronic adverse drug reactions. Finally, disulfiram-like reactions are associated with many other substances that have an ethanol-like mechanism of toxicity with disulfiram.

  • Disulfiram is usually prescribed at an initial dose of 500 mg/d for 1-2 weeks, followed by a maintenance dose of 125-500 mg/d. Close monitoring for adverse reactions is required.
  • Disulfiram use is associated with adverse reactions at a rate of approximately 1 per 200-2000 each year. Frequently reported aversive reactions are mainly hepatic, neurologic, dermatologic, and psychiatric.
  • Drowsiness is the most common side effect and occurs in up to 5% of patients. It generally resolves after 2 weeks of treatment. Other side effects include dyspnea, sweating, alteration of taste, vasodilation, impotence, amblyopia, dizziness, headache, ataxia, polyneuritis, psychosis, and hypertension.
  • Acute disulfiram overdose is uncommon. In adults, clinical manifestations after acute overdose are rare with doses less than 3 g. Ingestion of 10-30 g may be lethal. Toxicity in children has been reported after ingestion of 2.5 g of disulfiram. Symptoms of overdose in children are mostly neurologic.
Previous
 
 
Contributor Information and Disclosures
Author

Samara Soghoian, MD, MA Clinical Assistant Professor of Emergency Medicine, New York University School of Medicine, Bellevue Hospital Center

Samara Soghoian, MD, MA is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Medical Toxicology, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

José Eric Díaz-Alcalá, MD, FAAEM, FACMT Medical and Executive Co-Director, Medical Toxicology Consultant, Administración de Servicios Médicos de Puerto Rico, ASEM Poison Control Center; Chief, Emergency Medicine Unit, Medical Toxicology Consultant, VA Caribbean Healthcare System

José Eric Díaz-Alcalá, MD, FAAEM, FACMT is a member of the following medical societies: American Academy of Emergency Medicine, American College of Medical Toxicology

Disclosure: Nothing to disclose.

Sage W Wiener, MD Assistant Professor, Department of Emergency Medicine, State University of New York Downstate Medical Center; Director of Medical Toxicology, Department of Emergency Medicine, Kings County Hospital Center

Sage W Wiener, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Medical Toxicology, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

John T VanDeVoort, PharmD Regional Director of Pharmacy, Sacred Heart and St Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

John G Benitez, MD, MPH Associate Professor, Department of Medicine, Medical Toxicology, Vanderbilt University Medical Center; Managing Director, Tennessee Poison Center

John G Benitez, MD, MPH is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Emergency Medicine, American College of Medical Toxicology, American College of Preventive Medicine, Undersea and Hyperbaric Medical Society, Wilderness Medical Society, American College of Occupational and Environmental Medicine

Disclosure: Nothing to disclose.

Chief Editor

Asim Tarabar, MD Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure: Nothing to disclose.

Additional Contributors

David C Lee, MD Research Director, Department of Emergency Medicine, Associate Professor, North Shore University Hospital and New York University Medical School

David C Lee, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Medical Toxicology, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

References
  1. Crowley P. Long-term drug treatment of patients with alcohol dependence. Aust Prescr. 2015 Apr. 38 (2):41-43. [Medline].

  2. Baker JR, Jatlow P, McCance-Katz EF. Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend. 2007 Mar 16. 87(2-3):202-9. [Medline].

  3. Kong D, Kotraiah V. Modulation of aldehyde dehydrogenase activity affects (±)-4-hydroxy-2E-nonenal (HNE) toxicity and HNE-protein adduct levels in PC12 cells. J Mol Neurosci. 2012 Jul. 47(3):595-603. [Medline].

  4. Mowry JB, Spyker DA, Brooks DE, McMillan N, Schauben JL. 2014 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 32nd Annual Report. Clin Toxicol (Phila). 2015 Dec. 53 (10):962-1147. [Medline].

  5. Vaccari A, Ferraro L, Saba P, et al. Differential mechanisms in the effects of disulfiram and diethyldithiocarbamate intoxication on striatal release and vesicular transport of glutamate. J Pharmacol Exp Ther. 1998 Jun. 285(3):961-7. [Medline].

  6. Filosto M, Tentorio M, Broglio L, et al. Disulfiram neuropathy: two cases of distal axonopathy. Clin Toxicol (Phila). 2008 Apr. 46(4):314-6. [Medline].

  7. Burman WJ, Terra M, Breese P, et al. Lack of toxicity from concomitant directly observed disulfiram and isoniazid-containing therapy for active tuberculosis. Int J Tuberc Lung Dis. 2002 Sep. 6(9):839-42. [Medline].

  8. Vaglini F, Viaggi C, Piro V, Pardini C, Gerace C, Scarselli M, et al. Acetaldehyde and parkinsonism: role of CYP450 2E1. Front Behav Neurosci. 2013. 7:71. [Medline]. [Full Text].

  9. Milne HJ, Parke TR. Hypotension and ST depression as a result of disulfiram ethanol reaction. Eur J Emerg Med. 2007 Aug. 14(4):228-9. [Medline].

  10. de Mari M, De Blasi R, Lamberti P, et al. Unilateral pallidal lesion after acute disulfiram intoxication: a clinical and magnetic resonance study. Mov Disord. 1993 Apr. 8(2):247-9. [Medline].

  11. Ellenhorn MJ. Disulfiram. Ellenhorn's Medical Toxicology. Lippincott Williams & Wilkins; 1997. Vol 2: 1356-62.

  12. Enghusen Poulsen H, Loft S, Andersen JR, et al. Disulfiram therapy--adverse drug reactions and interactions. Acta Psychiatr Scand Suppl. 1992. 369:59-65; discussion 65-6. [Medline].

  13. Forns X, Caballeria J, Bruguera M, et al. Disulfiram-induced hepatitis. Report of four cases and review of the literature. J Hepatol. 1994 Nov. 21(5):853-7. [Medline].

  14. Heath MJ, Pachar JV, Perez Martinez AL, et al. An exceptional case of lethal disulfiram-alcohol reaction. Forensic Sci Int. 1992 Sep. 56(1):45-50. [Medline].

  15. Hirschberg M, Ludolph A, Grotemeyer KH, et al. Development of a subacute tetraparesis after disulfiram intoxication. Case report. Eur Neurol. 1987. 26(4):222-8. [Medline].

  16. Kirubakaran V, Faiman MD, Liskow B, et al. Plasma measurements of disulfiram and its metabolites in a case of severe disulfiram-ethanol reaction. Psychiatr J Univ Ott. 1986 Sep. 11(3):166-8. [Medline].

  17. Krauss JK, Mohadjer M, Wakhloo AK, et al. Dystonia and akinesia due to pallidoputaminal lesions after disulfiram intoxication. Mov Disord. 1991. 6(2):166-70. [Medline].

  18. Kuffner EK. Disulfiram and disulfiram-like reactions. Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, Lewin NA, Nelson LS. Goldfrank’s Toxicology Emergencies. 8th ed. McGraw-Hill; 2006. 1176-1183.

  19. Laplane D, Attal N, Sauron B, et al. Lesions of basal ganglia due to disulfiram neurotoxicity. J Neurol Neurosurg Psychiatry. 1992 Oct. 55(10):925-9. [Medline].

  20. Mahajan P, Lieh-Lai MW, Sarnaik A, et al. Basal ganglia infarction in a child with disulfiram poisoning. Pediatrics. 1997 Apr. 99(4):605-8. [Medline].

  21. Nasrallah HA. Vulnerability to disulfiram psychosis. West J Med. 1979 Jun. 130(6):575-7. [Medline].

  22. Stransky G, Lambing MK, Simmons GT, et al. Methemoglobinemia in a fatal case of disulfiram-ethanol reaction. J Anal Toxicol. 1997 Mar-Apr. 21(2):178-9. [Medline].

  23. Zorzon M, Mase G, Biasutti E, et al. Acute encephalopathy and polyneuropathy after disulfiram intoxication. Alcohol Alcohol. 1995 Sep. 30(5):629-31. [Medline].

 
Previous
Next
 
The pathway of ethanol metabolism. Disulfiram reduces the rate of oxidation of acetaldehyde by competing with the cofactor nicotinamide adenine dinucleotide (NAD) for binding sites on aldehyde dehydrogenase (ALDH).
Disulfiram, prodrug for active metabolites.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.